These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32171288)

  • 21. The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.
    Korkmaz M; Eryılmaz MK; Koçak MZ; Er MM; Hendem E; Demirkıran A; Araz M; Artaç M
    Eur J Clin Pharmacol; 2024 Jun; 80(6):941-947. PubMed ID: 38478093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
    Choueiri TK; Hessel C; Halabi S; Sanford B; Michaelson MD; Hahn O; Walsh M; Olencki T; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; George D; Morris MJ
    Eur J Cancer; 2018 May; 94():115-125. PubMed ID: 29550566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
    Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
    Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
    Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
    BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
    Capri S; Porta C; Delea TE
    Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
    Isaacsson Velho P; Nardo M; Souza MCLA; Bonadio RRCC; Marta GN; Muniz DQB; Bastos DA; Dzik C
    J Glob Oncol; 2018 Aug; 4():1-10. PubMed ID: 30199304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
    McCormack PL
    Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
    Kilonzo M; Hislop J; Elders A; Fraser C; Bissett D; McClinton S; Mowatt G; Vale L
    Pharmacoeconomics; 2013 Jan; 31(1):15-24. PubMed ID: 23329590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
    Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
    PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
    Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
    Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
    Lai JS; Beaumont JL; Diaz J; Khan S; Cella D
    Cancer; 2016 Jan; 122(2):287-95. PubMed ID: 26457466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).
    Rodriguez-Vida A; Bamias A; Esteban E; Saez MI; Lopez-Brea M; Castellano D; Caballero C; Gonzalez-Larriba JL; Calvo E; Macia S; Ravaud A; Bellmunt J
    BJU Int; 2020 Nov; 126(5):559-567. PubMed ID: 32654362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
    Xu CF; Johnson T; Garcia-Donas J; Choueiri TK; Sternberg CN; Davis ID; Bing N; Deen KC; Xue Z; McCann L; Esteban E; Whittaker JC; Spraggs CF; Rodríguez-Antona C; Pandite LN; Motzer RJ
    Br J Cancer; 2015 Mar; 112(7):1190-8. PubMed ID: 25695485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].
    Trump D
    Urol Oncol; 2016 May; 34(5):251. PubMed ID: 25937427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
    Escudier B; Porta C; Bono P; Powles T; Eisen T; Sternberg CN; Gschwend JE; De Giorgi U; Parikh O; Hawkins R; Sevin E; Négrier S; Khan S; Diaz J; Redhu S; Mehmud F; Cella D
    J Clin Oncol; 2014 May; 32(14):1412-8. PubMed ID: 24687826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
    Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
    Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
    Tannir NM; Msaouel P; Ross JA; Devine CE; Chandramohan A; Gonzalez GMN; Wang X; Wang J; Corn PG; Lim ZD; Pruitt L; Karam JA; Wood CG; Zurita AJ
    Eur Urol Oncol; 2020 Oct; 3(5):687-694. PubMed ID: 31272939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study.
    Chen J; Ye W; Jiang W; Li X; Liu R; Lin B; Xiang J; Tian W; Bai J; Zuo T; Lin B; Guo Y; Zheng S
    Transl Androl Urol; 2021 Mar; 10(3):1321-1331. PubMed ID: 33850766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma.
    Qin SK; Jin J; Guo J; Wang JW; Zhou FJ; Huang YR; Ren XB; Ye DW; Pan S; Sajben P; Wang Q
    Future Oncol; 2018 Aug; 14(18):1835-1845. PubMed ID: 29717651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
    Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
    JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.